Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHGA0S)

• Drug Name: PF-07799933 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHGA0S

Molecule-Related Drug Atlas

Drug(s) Targeting Serine/threonine-protein kinase B-raf (BRAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[2]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[3]
LGX818	DMNQXV8	Melanoma	2C30	Approved	[4]
PLX8394	DMRTD7I	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
BGB-283	DMVYTG7	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
ARQ 736	DMP9ZT1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
RO-5212054	DML4C3Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
ASN003	DMJCX6D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
BMS-908662	DM3K8VM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase B-raf (BRAF)	TTWCGQT	BRAF_HUMAN	Inhibitor	[1]

References

• [1] ClinicalTrials.gov (NCT05355701) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
• [6] Clinical pipeline report, company report or official report of Ambit Biosciences.
• [7] BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
• [8] National Cancer Institute Drug Dictionary (drug id 688029).
• [9] National Cancer Institute Drug Dictionary (drug id 680347).
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of Exelixis (2011).